Nine participants had serial plasma samples available for cytokine measurement. In participants with high baseline levels of the pro-inflammatory cytokines IL1b, IL6 or IL8, these cytokines trended down rapidly after initiation of lenalidomide. By contrast, IL10, an anti-inflammatory cytokine, and IL12, a TH1-promoting immune stimulatory cytokine, trended up.